Analysts at Bank of America started coverage on shares of Madrigal Pharmaceuticals (NASDAQ:MDGL – Get Free Report) in a research report issued to clients and investors on Monday, Marketbeat Ratings reports. The firm set an “underperform” rating and a $150.00 price target on the biopharmaceutical company’s stock. Bank of America‘s target price would suggest a […]
3 Potential Biopharma Buyout Targets seekingalpha.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from seekingalpha.com Daily Mail and Mail on Sunday newspapers.
Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Get Free Report) fell 3.3% during mid-day trading on Wednesday . The company traded as low as $225.22 and last traded at $225.22. 43,731 shares were traded during trading, a decline of 92% from the average session volume of 525,723 shares. The stock had previously closed at $232.98. […]
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Get Free Report) has received an average rating of “Moderate Buy” from the ten research firms that are presently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a hold recommendation and nine have given a buy recommendation to the company. The average 12-month price […]
Rezdiffra is the first and only medication approved by the FDA for the treatment of NASH (also known as "MASH") • First patients have received Rezdiffra via…